Rigel Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary

Rigel Pharmaceuticals

05/03/2024 23:34

* Rigel Pharmaceuticals Inc  RIGL.OQ  reported quarterly
breakeven
results​​ per share for the quarter ended in December, lower
than the same quarter last year, when the company reported EPS
of 1 cents.  The mean expectation of six analysts for the
quarter was for a loss of 3 cents per share. Wall Street
expected results to range from -5 cents to -1 cents per share.
    * Revenue fell 30.2% to $35.79 million from a year ago;
analysts
expected $34.10 million. 
    * Rigel Pharmaceuticals Inc's reported EPS for the quarter
was
breakeven results​.
    * The company reported quarterly net income of $737
thousand.
    * Rigel Pharmaceuticals Inc shares had risen by 1.4% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 28.6%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell." 
    * Wall Street's median 12-month price target for Rigel
Pharmaceuticals Inc is $2.00 

This summary was machine generated from LSEG data March 5 at
11:33 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.03          0.00           Beat
 Sep. 30 2023      -0.07          -0.03          Beat
 Jun. 30 2023      -0.08          -0.04          Beat
 Mar. 31 2023      -0.10          -0.08          Beat